TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Metformin HCl in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, as Initial Therapy in Drug naïve Subjects With Type 2 Diabetes Mellitus, and the Effects of Colesevelam HCl on the Lipid Profile in Subjects With Pre Diabetes
Brief Summary: This is a 16-week double-blind, placebo-controlled (for colesevelam hydrochloride (HCl)) study in the type 2 diabetic subjects and pre-diabetic subjects. Diabetic participants will also be treated with open label, background,metformin HCl. Two-hundred sixty subjects with type 2 diabetes (T2DM) and 200 pre-diabetic subjects are planned to be be enrolled. Qualified subjects with T2DM will be randomized 1:1 to receive metformin HCl plus colesevelam HCl or metformin HCl plus placebo matching colesevelam HCl. Qualified pre-diabetic subjects will be randomized 1:1 to receive colesevelam HCl or matching placebo.


Options:
A: Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A
B: Arm Label: Diabetic Participants: Metformin HCl+Placebo for Colesevelam; Type: PLACEBO_COMPARATOR; Interventions: Drug: Metformin HCl and Colesevelam Placebo | Arm Label: Diabetic participants: Metformin HCl + Colesevelam; Type: EXPERIMENTAL; Interventions: Drug: Metformin HCl tablets and Colesevelam tablets | Arm Label: Pre-diabetic Participants: Colesevelam Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Colesevelam placebo | Arm Label: Pre-diabetes Participants: Colesevelam; Type: EXPERIMENTAL; Interventions: Drug: Colesevelam | Intervention Type: DRUG; Name: Metformin HCl and Colesevelam Placebo; Assigned to Arm(s): Diabetic Participants: Metformin HCl+Placebo for Colesevelam | Intervention Type: DRUG; Name: Metformin HCl tablets and Colesevelam tablets; Assigned to Arm(s): Diabetic participants: Metformin HCl + Colesevelam | Intervention Type: DRUG; Name: Colesevelam placebo; Assigned to Arm(s): Pre-diabetic Participants: Colesevelam Placebo | Intervention Type: DRUG; Name: Colesevelam; Assigned to Arm(s): Pre-diabetes Participants: Colesevelam
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma
Brief Summary: This study is to evaluate the efficacy, safety, and feasibility of sunitinib in 4/2 and 2/1 regimen in previously untreated metastatic RCC to select the most promising regimen, which should be used in further studies of this patient population.


Options:
A: Arm Label: Arm 1: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm 2: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm 1: Nivolumab | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Arm 2: Everolimus
B: Arm Label: Sunitinib 4/2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib 4/2 | Arm Label: Sunitinib 2/1; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib 2/1 | Intervention Type: DRUG; Name: Sunitinib 2/1; Assigned to Arm(s): Sunitinib 2/1 | Intervention Type: DRUG; Name: Sunitinib 4/2; Assigned to Arm(s): Sunitinib 4/2
C: Arm Label: RAD001; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): RAD001 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: Lenvatinib 18 mg plus Everolimus 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Lenvatinib 20 mg plus Pembrolizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Pembrolizumab | Arm Label: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg, Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib 50 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Supplementation With 2000 International Units (IU) Vitamin D, 1gm Calcium or Both on Calcium Absorption and Bone Mineralization in Children With Juvenile Rheumatoid Arthritis
Brief Summary: 2000 international units (IU) vitamin D, 1 gram (gm) calcium, or both given to children with Juvenile Rheumatoid Arthritis (JRA) may increase percent true calcium absorption, bone mineral turnover and/or bone mineralization.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: multiple micronutrients; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol, Dietary Supplement: Calcium, Dietary Supplement: Calcium and cholecalciferol, Drug: Placebo | Arm Label: Calcium; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol, Dietary Supplement: Calcium, Dietary Supplement: Calcium and cholecalciferol, Drug: Placebo | Arm Label: Cholecalciferol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol, Dietary Supplement: Calcium, Dietary Supplement: Calcium and cholecalciferol, Drug: Placebo | Arm Label: Calcium and cholecalciferol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol, Dietary Supplement: Calcium, Dietary Supplement: Calcium and cholecalciferol, Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Calcium, Calcium and cholecalciferol, Cholecalciferol, Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium; Assigned to Arm(s): Calcium, Calcium and cholecalciferol, Cholecalciferol, Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium and cholecalciferol; Assigned to Arm(s): Calcium, Calcium and cholecalciferol, Cholecalciferol, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Calcium, Calcium and cholecalciferol, Cholecalciferol, Placebo
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: No supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: No supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 3
D: Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Drug: Multivitamins - vitamins B complex, C and E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Multivitamins - vitamins B complex, C and E; Assigned to Arm(s): Multivitamins | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Target-Controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by the Index Bispectral: Comparison Between Manual Perfusion and Automated Perfusion During Rigid Bronchoscopy
Brief Summary: The purpose of this study is to compare manual administration of propofol and remifentanil and dual closed-loop using bispectral index as the control variable during rigid bronchoscopy.


Options:
A: N/A
B: Arm Label: BIS Monitor guided algorithm; Type: EXPERIMENTAL; Interventions: Device: BIS Monitor guided algorithm | Arm Label: Volatile anesthetic guided algorithm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volatile anesthetic guided algorithm | Intervention Type: DEVICE; Name: BIS Monitor guided algorithm; Assigned to Arm(s): BIS Monitor guided algorithm | Intervention Type: BEHAVIORAL; Name: Volatile anesthetic guided algorithm; Assigned to Arm(s): Volatile anesthetic guided algorithm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Closed-loop system | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: TCI (Infusion Toolbox) | Intervention Type: DEVICE; Name: Closed-loop system; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: TCI (Infusion Toolbox); Assigned to Arm(s): 2
D: Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Propofol | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Study Comparing Tissue Conservation in Conventional Versus Mohs' Surgery of Basal Cell Carcinoma
Brief Summary: We have compared to types of surgery to assess which one leaves the smaller surgical defect.


Options:
A: Arm Label: standard surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard surgery | Arm Label: Mohs; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Mohs micrographic surgery | Intervention Type: PROCEDURE; Name: standard surgery; Assigned to Arm(s): standard surgery | Intervention Type: PROCEDURE; Name: Mohs micrographic surgery; Assigned to Arm(s): Mohs
B: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg
C: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
D: Arm Label: LDE225 200 mg; Type: EXPERIMENTAL; Interventions: Drug: LDE225 | Arm Label: LDE225 800 mg; Type: EXPERIMENTAL; Interventions: Drug: LDE225 | Intervention Type: DRUG; Name: LDE225; Assigned to Arm(s): LDE225 200 mg, LDE225 800 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Culturally Sensitive Depression Care Management for Latino Primary Care Patients
Brief Summary: The purpose of this study is to determine whether telephonic depression care management can improve depression outcomes for Latino primary care patients who are enrolled in Medicaid and are receiving an antidepressant from their primary care doctor.


Options:
A: Intervention Type: PROCEDURE; Name: Standard Quality Improvement; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Patient-centered Intervention; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: telephone depression care management | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: telephone depression care management; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative depression care management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Collaborative depression care management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: Care manager outreach and monitoring; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Continuous Infusion of Fentanyl for Pain Control in Preterm Newborn on Mechanical Ventilation
Brief Summary: The objective of this randomized, double-blind trial is to compare the efficacy and safety of 2 therapeutic regimens of fentanyl administration in a population of preterm newborns of GA \<= 32 weeks in MV:

* Group A) continuous infusion of Fentanyl + open label boluses of Fentanyl;
* Group B) continuous infusion of placebo + open label boluses of Fentanyl.


Options:
A: Arm Label: Paracetamol effect on ductus; Type: EXPERIMENTAL; Interventions: Drug: paracetamol, Drug: 0.45 % saline solution | Arm Label: Paracetamol effect on pain; Type: EXPERIMENTAL; Interventions: Drug: paracetamol, Drug: 0.45 % saline solution | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): Paracetamol effect on ductus, Paracetamol effect on pain | Intervention Type: DRUG; Name: 0.45 % saline solution; Assigned to Arm(s): Paracetamol effect on ductus, Paracetamol effect on pain
B: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
D: Arm Label: fentanyl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fentanyl | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 5% glucose solution | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): fentanyl | Intervention Type: DRUG; Name: 5% glucose solution; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study
Brief Summary: This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban will also be studied.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin titrated to an INR of 2.5-3.0 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel 75 | Intervention Type: DRUG; Name: Warfarin titrated to an INR of 2.5-3.0; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Clopidogrel 75; Assigned to Arm(s): 3
B: Arm Label: Rivaroxaban 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Other: Standard of care for heart failure and coronary artery disease | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of care for heart failure and coronary artery disease | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban 2.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Standard of care for heart failure and coronary artery disease; Assigned to Arm(s): Placebo, Rivaroxaban 2.5 mg
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)
D: Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): aspirin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): warfarin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study
Brief Summary: This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban will also be studied.


Options:
A: Intervention Type: DRUG; Name: enoxaparin sodium; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): N/A
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)
D: Arm Label: Heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Drug: Placebo | Arm Label: Nadroparin; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Heparin, Drug: Nadroparin | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin, Placebo | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): Nadroparin, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Heparin, Nadroparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study
Brief Summary: This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban will also be studied.


Options:
A: Intervention Type: DRUG; Name: enoxaparin sodium; Assigned to Arm(s): N/A
B: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavioral Treatment of High Blood Pressure
Brief Summary: This study is an NIH-funded clinical trial conducted at Duke Medical Center evaluating the effects of the DASH diet alone and combined with a behavioral weight loss program on blood pressure and various vascular measures. Eligible patients must be unmedicated with blood pressure values ranging from approximately 130/85 to 159/99. Our primary hypothesis are as follows: (1) The DASH diet alone and combined with a behavioral weight management program will result in greater BP reductions than Usual Care controls at the end of the 4 month treatment period; (2) The DASH diet in combination with a behavioral weight management program will be more effective in lowering BP than the DASH diet alone; (3) The DASH diet alone and the DASH diet combined with the behavioral weight management program will result in greater improvements in cardiac, metabolic, and vascular function compared to the control condition; and (4) The combined DASH diet and weight management intervention also will be the most effective treatment in maintaining BP reductions at 1-year follow-up.


Options:
A: Arm Label: Mediterranean Diet Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Mediterranean diet Intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mediterranean diet Intervention; Assigned to Arm(s): Mediterranean Diet Intervention group
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Diet with increased intake of rye bread, berries and fish | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Increased intake of whole grain and rye bread | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control diet with decreased intake of rye bread, berries and fish | Intervention Type: DIETARY_SUPPLEMENT; Name: Diet with increased intake of rye bread, berries and fish; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: Increased intake of whole grain and rye bread; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Control diet with decreased intake of rye bread, berries and fish; Assigned to Arm(s): C
C: Arm Label: DASH diet; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet | Arm Label: DASH diet plus Weight loss; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet plus Weight loss | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: DASH diet; Assigned to Arm(s): DASH diet | Intervention Type: BEHAVIORAL; Name: DASH diet plus Weight loss; Assigned to Arm(s): DASH diet plus Weight loss
D: Arm Label: Experimental diet; Type: EXPERIMENTAL; Interventions: Other: Experimental diet | Arm Label: Control diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Control diet | Intervention Type: OTHER; Name: Experimental diet; Assigned to Arm(s): Experimental diet | Intervention Type: OTHER; Name: Control diet; Assigned to Arm(s): Control diet

Answer: C